Heba T Abdel-Mohsen

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Molecular Docking

Bacillus Subtilis

Top Venues

Archiv der Pharmazie

Molecules (Basel, Switzerland)

Drug development research

This page only lists publications with an associated author ORCID identifier.

Publications

Yasmin M Syam, Somaia S Abd El-Karim, Heba T Abdel-Mohsen
Quinazoline-oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies. Archiv der Pharmazie (2024)
Heba T Abdel-Mohsen, Manal M Anwar, Nesreen S Ahmed, Somaia S Abd El-Karim, Sameh H Abdelwahed
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present). Molecules (Basel, Switzerland) 29 (4) (2024)
Heba T Abdel-Mohsen, Amira M Nageeb
Benzimidazole-dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions. RSC advances 14 (39) (2024)
Heba T Abdel-Mohsen, Manal M Anwar, Nesreen S Ahmed, Somaia S Abd El-Karim, Sameh H Abdelwahed
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present). Molecules (Basel, Switzerland) 29 (4) (2024)
Heba T Abdel-Mohsen, Yasmin M Syam, Mahmoud S Abd El-Ghany, Somaia S Abd El-Karim
Benzimidazole-oxindole hybrids: A novel class of selective dual CDK2 and GSK-3β inhibitors of potent anticancer activity. Archiv der Pharmazie (2024)
Heba T Abdel-Mohsen, Manal M Anwar, Nesreen S Ahmed, Somaia S Abd El-Karim, Sameh H Abdelwahed
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present). Molecules (Basel, Switzerland) 29 (4) (2024)
Heba T Abdel-Mohsen, Amira M Nageeb, Iman A Y Ghannam
Diphenyl urea-benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents. Drug development research 85 (6) (2024)
Heba T Abdel-Mohsen, Amira M Nageeb, Iman A Y Ghannam
Diphenyl urea-benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents. Drug development research 85 (6) (2024)
Heba T Abdel-Mohsen, Ahmed M El Kerdawy, Andrea Petreni, Claudiu T Supuran
Novel benzenesulfonamide-thiouracil conjugates with a flexible N-ethyl acetamide linker as selective CA IX and CA XII inhibitors. Archiv der Pharmazie (2022)
Heba T Abdel-Mohsen, Mohamed A Omar, Andrea Petreni, Claudiu T Supuran
Novel 2-substituted thioquinazoline-benzenesulfonamide derivatives as carbonic anhydrase inhibitors with potential anticancer activity. Archiv der Pharmazie 355 (12) (2022)
Heba T Abdel-Mohsen, Andrea Petreni, Claudiu T Supuran
Investigation of the carbonic anhydrase inhibitory activity of benzenesulfonamides incorporating substituted fused-pyrimidine tails. Archiv der Pharmazie 355 (11) (2022)
Heba T Abdel-Mohsen, Amira Abood, Keith J Flanagan, Alina Meindl, Elisabeth Sitte, Hoda I El Diwani
Synthesis, crystal structure, and ADME prediction studies of novel imidazopyrimidines as antibacterial and cytotoxic agents. Archiv der Pharmazie 353 (3) (2020)
Heba T Abdel-Mohsen, Eman A Abd El-Meguid, Ahmed M El Kerdawy, Abeer E E Mahmoud, Mamdouh M Ali
Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Archiv der Pharmazie 353 (4) (2020)
Heba T Abdel-Mohsen, Adel S Girgis, Abeer E E Mahmoud, Mamdouh M Ali, Hoda I El Diwani
New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. Archiv der Pharmazie 352 (11) (2019)